Početna › Burkittov limfom › Georgia
Kliničke studije za Burkittov limfom u državi Georgia
12 studija za Burkittov limfom traži sudionike na lokacijama u državi Georgia.
Gradovi u državi Georgia
Službeni tekst studije (engleski)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- i još 1
U tijeku regrutacijaFaza 2
366 Days – 46 Years · Oba spola · Ažurirano 2. lis 2026. · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Augusta University Medical Center, Augusta
U tijeku regrutacijaFaza 3
Od 18 do 39 godina · Oba spola · Ažurirano 2. lis 2026. · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
U tijeku regrutacijaOpažajna studija
Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
U tijeku regrutacijaFaza 2
365 Days · Oba spola · Ažurirano 25. ruj 2026. · NCT06317662Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Memorial Health University Medical Center, Savannah
U tijeku regrutacijaFaza 2
Od 1 do 30 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- i još 1
U tijeku regrutacijaFaza 3
365 Days – 25 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Healthcare of Atlanta at Egleston, Atlanta
U tijeku regrutacijaFaza 2
Od 7 do 25 godina · Oba spola · Ažurirano 19. kol 2026. · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Atlanta
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT06137118Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Winship Cancer Institute, Emory University, Atlanta
- Augusta Cancer Center, Augusta
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 5. stu 2025. · NCT04260022The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Healthcare of Atlanta, Atlanta
U tijeku regrutacijaFaza 2
Od 1 do 25 godina · Oba spola · Ažurirano 4. svi 2025. · NCT03509961Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.